343 related articles for article (PubMed ID: 26630533)
1. Trastuzumab for HER2+ metastatic breast cancer in clinical practice: Cardiotoxicity and overall survival.
Rossi M; Carioli G; Bonifazi M; Zambelli A; Franchi M; Moja L; Zambon A; Corrao G; La Vecchia C; Zocchetti C; Negri E
Eur J Cancer; 2016 Jan; 52():41-9. PubMed ID: 26630533
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.
Rossi V; Nolè F; Redana S; Adamoli L; Martinello R; Aurilio G; Verri E; Sapino A; Viale G; Aglietta M; Montemurro F
Breast; 2014 Feb; 23(1):44-9. PubMed ID: 24210572
[TBL] [Abstract][Full Text] [Related]
3. Estimated Life-Years Saved in Women with HER2-Positive Metastatic Breast Cancer Receiving First-Line Trastuzumab and Pertuzumab in the United States.
Danese MD; Masaquel A; Santos E; Brammer M; Lee A; Lalla D
Value Health; 2015 Sep; 18(6):876-83. PubMed ID: 26409616
[TBL] [Abstract][Full Text] [Related]
4. Long term survival of HER2-positive early breast cancer treated with trastuzumab-based adjuvant regimen: a large cohort study from clinical practice.
Bonifazi M; Franchi M; Rossi M; Zambelli A; Moja L; Zambon A; Corrao G; La Vecchia C; Zocchetti C; Negri E
Breast; 2014 Oct; 23(5):573-8. PubMed ID: 24934637
[TBL] [Abstract][Full Text] [Related]
5. The role of p95HER2 in trastuzumab resistance in breast cancer.
Ozkavruk Eliyatkin N; Aktas S; Ozgur H; Ercetin P; Kupelioglu A
J BUON; 2016; 21(2):382-9. PubMed ID: 27273948
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of trastuzumab in first-line HER2+ metastatic breast cancer after failure in adjuvant setting: a controlled cohort study.
Negri E; Zambelli A; Franchi M; Rossi M; Bonifazi M; Corrao G; Moja L; Zocchetti C; La Vecchia C
Oncologist; 2014 Dec; 19(12):1209-15. PubMed ID: 25355843
[TBL] [Abstract][Full Text] [Related]
7. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
Pivot X; Romieu G; Debled M; Pierga JY; Kerbrat P; Bachelot T; Lortholary A; Espié M; Fumoleau P; Serin D; Jacquin JP; Jouannaud C; Rios M; Abadie-Lacourtoisie S; Tubiana-Mathieu N; Cany L; Catala S; Khayat D; Pauporté I; Kramar A;
Lancet Oncol; 2013 Jul; 14(8):741-8. PubMed ID: 23764181
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
Burris HA; Rugo HS; Vukelja SJ; Vogel CL; Borson RA; Limentani S; Tan-Chiu E; Krop IE; Michaelson RA; Girish S; Amler L; Zheng M; Chu YW; Klencke B; O'Shaughnessy JA
J Clin Oncol; 2011 Feb; 29(4):398-405. PubMed ID: 21172893
[TBL] [Abstract][Full Text] [Related]
9. Trastuzumab-Related Cardiotoxicity and Cardiac Care in Patients With HER2 Positive Metastatic Breast Cancer.
Calvillo-Argüelles O; Abdel-Qadir H; Suntheralingam S; Michalowska M; Amir E; Thavendiranathan P
Am J Cardiol; 2020 Apr; 125(8):1270-1275. PubMed ID: 32087998
[TBL] [Abstract][Full Text] [Related]
10. The Clinical Efficacy and Cardiotoxicity of Fixed-Dose Monthly Trastuzumab in HER2-Positive Breast Cancer: A Single Institutional Analysis.
Wu YY; Huang TC; Tsai TN; Chen JH; Dai MS; Chang PY; Ho CL; Ye RH; Chung TR; Chen YC; Chao TY
PLoS One; 2016; 11(3):e0151112. PubMed ID: 26953588
[TBL] [Abstract][Full Text] [Related]
11. Use of trastuzumab for HER2-positive metastatic breast cancer in daily practice: a population-based study focusing on the elderly.
van Rooijen JM; de Munck L; Teeuwen GM; de Graaf JC; Jansman FG; Boers JE; Siesling S
Anticancer Drugs; 2016 Feb; 27(2):127-32. PubMed ID: 26473525
[TBL] [Abstract][Full Text] [Related]
12. Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer.
Mantarro S; Rossi M; Bonifazi M; D'Amico R; Blandizzi C; La Vecchia C; Negri E; Moja L
Intern Emerg Med; 2016 Feb; 11(1):123-40. PubMed ID: 26712595
[TBL] [Abstract][Full Text] [Related]
13. Time to first tumor progression as outcome predictor of a second trasuzumab-based therapy beyond progression in HER-2 positive metastatic breast cancer.
Metro G; Giannarelli D; Gemma D; Lanzetta G; Ciccarese M; Papaldo P; Gamucci T; Lorusso V; Mottolese M; Magnolfi E; Cognetti F; Fabi A
Breast J; 2010; 16(1):66-72. PubMed ID: 19889170
[TBL] [Abstract][Full Text] [Related]
14. Survival and cardiac toxicity in patients with HER2-positive, metastatic breast cancer treated with trastuzumab in routine clinical practice.
Vasista A; Ryan L; Naher S; Moylan E; Stockler MR; Wilcken N; Kiely BE
Asia Pac J Clin Oncol; 2020 Feb; 16(1):34-38. PubMed ID: 31657878
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab therapy in Australia: which patients with HER2+ metastatic breast cancer are assessed for cardiac function?
Lu CY; Srasuebkul P; Drew AK; Chen K; Ward RL; Pearson SA
Breast; 2013 Aug; 22(4):482-7. PubMed ID: 23664254
[TBL] [Abstract][Full Text] [Related]
16. Trastuzumab-related cardiotoxicity in early breast cancer: a cohort study.
Bonifazi M; Franchi M; Rossi M; Moja L; Zambelli A; Zambon A; Corrao G; La Vecchia C; Zocchetti C; Negri E
Oncologist; 2013; 18(7):795-801. PubMed ID: 23823908
[TBL] [Abstract][Full Text] [Related]
17. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.
Blackwell KL; Burstein HJ; Storniolo AM; Rugo HS; Sledge G; Aktan G; Ellis C; Florance A; Vukelja S; Bischoff J; Baselga J; O'Shaughnessy J
J Clin Oncol; 2012 Jul; 30(21):2585-92. PubMed ID: 22689807
[TBL] [Abstract][Full Text] [Related]
18. Factors predicting trastuzumab-related cardiotoxicity in a real-world population of women with HER2+ breast cancer.
Naumann D; Rusius V; Margiotta C; Nevill A; Carmichael A; Rea D; Sintler M
Anticancer Res; 2013 Apr; 33(4):1717-20. PubMed ID: 23564821
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer.
Tarantini L; Cioffi G; Gori S; Tuccia F; Boccardi L; Bovelli D; Lestuzzi C; Maurea N; Oliva S; Russo G; Faggiano P;
J Card Fail; 2012 Feb; 18(2):113-9. PubMed ID: 22300778
[TBL] [Abstract][Full Text] [Related]
20. Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch Practice: A Study of the Southeast Netherlands Breast Cancer Consortium.
Seferina SC; de Boer M; Derksen MW; van den Berkmortel F; van Kampen RJ; van de Wouw AJ; Joore M; Peer PG; Voogd AC; Tjan-Heijnen VC
Oncologist; 2016 May; 21(5):555-62. PubMed ID: 27009939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
